The news: Eli Lilly is launching Lilly Employer Connect, a direct-to-employer platform for its obesity drug Zepbound, offering flat pricing for companies.

• Zepbound’s multi-dose KwikPen will cost $449 per month for all prescriptions. Employers can set cost-sharing levels to determine how the cost will be split with workers.
• The platform is rolling out with 15 plan administrators for employers to contract with, including GoodRx, Mark Cuban Cost Plus Drug Company, Teladoc Health, and Waltz Health.

Why it matters: As GLP-1 drugmakers face pressure to expand workplace access, they are hitting a financial wall as employers—the traditional gatekeepers of prescription benefits—exclude obesity treatments to shield themselves from surging pharmacy costs.

• Just 19% of employers cover the cost of GLP-1 drugs for weight loss, per KFF’s Employer Health Benefits survey in October.
• Employers expect pharmacy costs to climb 11% to 12% in 2026, with many noting obesity drugs are driving the increase, according to an August Business Group on Health survey.

Still, many employers believe GLP-1 weight loss drug coverage is a valuable benefit and would ideally like to cover the medications if they weren’t so costly. Among companies with 5,000 or more employees that cover the drugs for weight loss, 86% call it important or very important for employee satisfaction, along with 59% of midsize firms (200 to 4,999 workers), per KFF.

Implications for employers and drugmakers: Lilly’s move puts a major manufacturer behind the employer GLP-1 cost-sharing model that smaller players like GoodRx and Waltz Health have launched on their own. That backing could help turn a niche approach into a more mainstream option.

• For employers, the program offers clearer pricing and flexible cost sharing, although it may also increase pressure from workers to offer some level of coverage.
• For drugmakers, it opens another path to reach potential customers with employer coverage that exclude GLP-1s for weight loss. It also tests a new way to sell higher-cost treatments in the employer market.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.